Kenneth Donald Greis

Prof. Kenneth Donald Greis

orcid

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2018 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
HHHuilin Huang
Huilin Huang
HWHengyou Weng
Hengyou Weng
WSWenju Sun
Wenju Sun
XQXi Qin
Xi Qin
HSHailing Shi
Hailing Shi
JCJianjun Chen
Jianjun Chen
N6-methyladenosine (m6A) is the most prevalent modification in eukaryotic messenger RNAs (mRNAs) and is interpreted by its readers, such as YTH domain-containing proteins, to regulate mRNA fate. Here, we report the insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs; including IGF2BP1/2/3) as a distinct family of m6A readers that target thousands of mRNA transcripts through recognizing the consensus GG(m6A)C sequence. In contrast to the mRNA-decay-promoting function of YTH domain-containing family protein 2, IGF2BPs promote the stability and storage of their target mRNAs (for example, MYC) in an m6A-dependent manner under normal and stress conditions and therefore affect gene expression output. Moreover, the K homology domains of IGF2BPs are required for their recognition of m6A and are critical for their oncogenic functions. Thus, our work reveals a different facet of the m6A-reading process that promotes mRNA stability and translation, and highlights the functional importance of IGF2BPs as m6A readers in post-transcriptional gene regulation and cancer biology.

29 September 1998 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DFDavid W. Fry
David W. Fry
ABAlexander J. Bridges
Alexander J. Bridges
WDWilliam A. Denny
William A. Denny
ADAnnette Doherty
Annette Doherty
KGKenneth Donald Greis
Kenneth Donald Greis
EDEllen M. Dobrusin
Ellen M. Dobrusin
A class of high-affinity inhibitors is disclosed that selectively target and irreversibly inactivate the epidermal growth factor receptor tyrosine kinase through specific, covalent modification of a cysteine residue present in the ATP binding pocket. A series of experiments employing MS, molecular modeling, site-directed mutagenesis, and 14 C-labeling studies in viable cells unequivocally demonstrate that these compounds selectively bind to the catalytic domain of the epidermal growth factor receptor with a 1:1 stoichiometry and alkylate Cys-773. While the compounds are essentially nonreactive in solution, they are subject to rapid nucleophilic attack by this particular amino acid when bound in the ATP pocket. The molecular orientation and positioning of the acrylamide group in these inhibitors in relation to Cys-773 entirely support these results as determined from docking experiments in a homology-built molecular model of the ATP site. Evidence is also presented to indicate that the compounds interact in an analogous fashion with erbB2 but have no activity against the other receptor tyrosine kinases or intracellular tyrosine kinases that were tested in this study. Finally, a direct comparison between 6-acrylamido-4-anilinoquinazoline and an equally potent but reversible analog shows that the irreversible inhibitor has far superior in vivo antitumor activity in a human epidermoid carcinoma xenograft model with no overt toxicity at therapeutically active doses. The activity profile for this compound is prototypical of a generation of tyrosine kinase inhibitors with great promise for therapeutic significance in the treatment of proliferative disease.

15 January 2000 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
VSVeronica Sanchez
Veronica Sanchez
KGKenneth Donald Greis
Kenneth Donald Greis
ESElizabeth Sztul
Elizabeth Sztul
WBWillilam Britt
Willilam Britt
The assembly of human cytomegalovirus (HCMV) is thought to be similar to that which has been proposed for alphaherpesviruses and involve envelopment of tegumented subviral particles at the nuclear membrane followed by export from the cell by a poorly defined pathway. However, several studies have shown that at least two tegument virion proteins remain in the cytoplasm during the HCMV replicative cycle, thereby suggesting that HCMV cannot acquire its final envelope at the nuclear envelope. We investigated the assembly of HCMV by determining the intracellular trafficking of the abundant tegument protein pp150 (UL32) in productively infected human fibroblasts. Our results indicated that pp150 remained within the cytoplasm throughout the replicative cycle of HCMV and accumulated in a stable, juxtanuclear structure late in infection. Image analysis using a variety of cell protein-specific antibodies indicated that the pp150-containing structure was not a component of the endoplasmic reticulum, (ER), ER-Golgi intermediate compartment, cis or medial Golgi, or lysosomes. Partial colocalization of the structure was noted with the trans -Golgi network, and it appeared to lie in close proximity to the microtubule organizing center. Two additional tegument proteins (pp28 and pp65) and three envelope glycoproteins (gB, gH, and gp65) localized in this same structure late infection. This compartment appeared to be relatively stable since pp150, pp65, and the processed form of gB could be coisolated following cell fractionation. Our findings indicated that pp150 was expressed exclusively within the cytoplasm throughout the infectious cycle of HCMV and that the accumulation of the pp150 in this cytoplasmic structure was accompanied by at least five other virion proteins. These results suggested the possibility that this virus-induced structure represented a cytoplasmic site of virus assembly.

14 March 2000 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JSJeff B. Smaill
Jeff B. Smaill
GRGordon W. Rewcastle
Gordon W. Rewcastle
JLJoseph A. Loo
Joseph A. Loo
KGKenneth Donald Greis
Kenneth Donald Greis
OCO. Helen Chan
O. Helen Chan
WDWilliam A. Denny
William A. Denny

1 March 2015 in Developmental Cell
Verified
Journal Article
Closed access
KHKazuteru Hasegawa
Kazuteru Hasegawa
HSHo-Su Sin
Ho-Su Sin
SMSo Maezawa
So Maezawa
TBTyler J. Broering
Tyler J. Broering
AKAndrey V. Kartashov
Andrey V. Kartashov
SNSatoshi H. Namekawa
Satoshi H. Namekawa

1 February 1996 in Analytical Biochemistry
Verified
Journal Article
Closed access
KGKenneth Donald Greis
Kenneth Donald Greis
BHBradley K. Hayes
Bradley K. Hayes
FCFrank I. Comer
Frank I. Comer
MKMarion Kirkb
Marion Kirkb
SBStephen Barnesab
Stephen Barnesab
GHGerald W. Hart
Gerald W. Hart